Trials / Completed
CompletedNCT00097331
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Three Months Administration of SB-683699 (150 - 1200mg Twice Daily) in Subjects With Relapsing Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 261 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the effectiveness and safety of the investigational drug SB683699 in treating patients with relapsing multiple sclerosis (MS), using data from magnetic resonance imaging (MRI) scans as the main measure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB683699 |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2006-07-01
- Completion
- 2006-07-01
- First posted
- 2004-11-23
- Last updated
- 2015-04-13
Locations
11 sites across 5 countries: Belgium, Germany, Poland, Russia, Spain
Source: ClinicalTrials.gov record NCT00097331. Inclusion in this directory is not an endorsement.